CohBar Announces Commencement of Trading on the OTCQX Marketplace

Download as PDF

MENLO PARK, Calif.--(BUSINESS WIRE)-- CohBar, Inc. (OTCQX: CWBR and TSX-V: COB.U), an innovative biotechnology company focused on developing mitochondria-based therapeutics for diseases associated with aging, announced that its shares will begin trading today on the OTCQX® Best marketplace in the U.S. under the symbol “CWBR.” CohBar, a Delaware corporation based in California, began filing as a public company with the SEC in December 2014. Canaccord Genuity, a global investment banking and financial services company, will become a market maker in CohBar stock upon the commencement of OTCQX trading. The company’s shares will continue to trade on the TSX Venture Exchange, where it was listed in conjunction with its $11.2 million IPO in January 2015.

“We believe that CohBar’s pipeline of mitochondria-based therapeutics has the potential to significantly improve the healthy life-span of our aging population while, at the same time, creating significant value for our investors,” said Jon Stern, Chief Executive Officer of CohBar. “Our trading on the OTCQX provides U.S. investors with the opportunity to acquire CohBar shares, which until now have been readily available only in the Canadian marketplace. It also expands our market reach and audience to support future capital needs as we continue to advance our exploitation of this new arena of mitochondria-based medicine.”

U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for CohBar on www.otcmarkets.com.

About CohBar

CohBar (OTCQX: CWBR and TSXV: COB.U) is the leader in the research and development of mitochondria-based therapeutics (MBTs), an emerging class of drugs for the treatment of diseases associated with aging. MBTs originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. This groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. MBTs offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.

For additional company information, please visit www.cohbar.com.

About the OTCQX Marketplace

The OTCQX® Best marketplace is designed for established, investor-focused U.S. and international companies that meet high financial standards, demonstrate compliance with U.S. securities laws, are current in their disclosure and are sponsored by a professional third party advisor. The companies found on OTCQX are distinguished by the excellence of their operations and diligence with which they convey their qualifications. OTCQX includes over 350 world-class companies (ranging from global blue chips to U.S. high growth) with a combined total market capitalization of $1.4 trillion and $36 billion in annual dollar volume.

Forward-looking statements

This news release contains forward-looking statements, including: statements concerning: the company’s plans, prospects, resources and capabilities including statements concerning its ability to broaden its investor base in the U.S., its anticipated research and development activities, and the potential application of any therapeutic the company may develop. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by CohBar. These risks and uncertainties include CohBar’s ability to retain key personnel, expand its research operations and successfully advance its research programs. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CohBar, Inc.
Jeff Biunno, CFO, 973-841-1233
jeff.biunno@cohbar.com
or
MacDougall Biomedical Communications
Heather Savelle, 781-235-3060
hsavelle@macbiocom.com

Source: CohBar, Inc.

Released May 20, 2015